Generic Medicine Info
May be taken with or without food.
Uncorrected adrenal insufficiency or untreated thyrotoxicosis, acute MI or angina of effort; artificial rewarming (IV).
Special Precautions
Patients with adrenal insufficiency, myxoedema, severe and long-standing hypothyroidism; diabetes mellitus or diabetes insipidus; CV disease including angina, coronary artery disease and hypertension. Renal impairment. Children and elderly. Pregnancy and lactation. Monitoring Parameters Monitor TSH and triiodothyronine (T3) levels periodically during therapy; signs of hypo- or hyperthyroidism. Monitor thyroid function test (FT4, T3, T4) every 1-2 days in patients with myxoedema coma. Monitor cardiac function including blood pressure, heart rate, electrical activity (ECG) and recent or aggravated cardiac symptoms (e.g. chest pain, palpitations) regularly. Obtain bone mineral density test especially in postmenopausal women.
Adverse Reactions
Significant: Osteoporosis, MI, poor glycaemic control. Cardiac disorders: Angina, arrhythmia, cardiac failure, tachycardia. Gastrointestinal disorders: Diarrhoea, abdominal cramps, vomiting. General disorders and administration site conditions: Fever, heat intolerance. Immune system disorders: Hypersensitivity including (e.g. angioedema, urticaria). Injury, poisoning and procedural complications: Phlebitis. Investigations: Weight loss. Metabolism and nutrition disorders Increased appetite. Musculoskeletal and connective tissue disorders: Muscle weakness and cramps, twitching. Nervous system disorders: Excitability, headache, tremors. Psychiatric disorders: Anxiety, insomnia, nervousness, restlessness. Reproductive system and breast disorders: Menstrual irregularities, impaired fertility. Skin and subcutaneous tissue disorders: Excessive sweating, pruritus, rash, hair loss. Vascular disorders: Flushing, hypotension, hypertension.
Potentially Fatal: Cardiopulmonary arrest.
Drug Interactions
Increases serum plasma concentration of phenytoin. Increases the effect of oral anticoagulants (e.g. coumarin, phenindione) and sympathomimetic agents (e.g. epinephrine). May decrease the serum concentration of cardiac glycosides (e.g. digoxin). Decreased gastrointestinal absorption with bile acid sequestrants (e.g. colestyramine, colestipol). Decreased serum plasma concentration with carbamazepine, phenytoin. Decreased effect with oral contraceptives amiodarone, sertraline. Enhanced metabolism if concurrently administered with barbiturates (e.g. phenobarbital), primidone and rifampicin. Enhances receptor sensitivity to catecholamines when concurrently administered with TCAs (e.g. amitriptyline) resulting in increased risk for toxicity such as cardiac arrhythmias. Increased risk of hypertension and tachycardia when concurrently administered with ketamine. May alter the requirements of antidiabetic drugs. Accelerates the metabolism of β-blockers (e.g. propranolol).
Disclaimer: This information is independently developed by CIMS based on liothyronine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in